Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Rho signalling pathway inhibitors - BioAxone BioSciences

Drug Profile

Research programme: Rho signalling pathway inhibitors - BioAxone BioSciences

Alternative Names: BA 1016; BA 1037; BA 1049; BA 2017; BA 285; BA-1076; BA-207; BA-215; BA-240; Rhostatin™; ROCK2 inhibitors - BioAxone BioSciences

Latest Information Update: 05 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioAxone Therapeutic
  • Developer BioAxone Biosciences; BioAxone Therapeutic
  • Class Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Neuroprotectants; Small molecules
  • Mechanism of Action Rho GTP-binding protein inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cavernous haemangioma; Spinal cord injuries; Stroke
  • No development reported Glaucoma
  • Discontinued Cancer; Cancer metastases; Cardiovascular disorders; CNS trauma; Optic nerve disorders; Retinal disorders

Most Recent Events

  • 27 Sep 2018 BioAxone BioSciences plans phase I proof of concept trial and phase II trial of BA 1049 for Spinal cord injuries
  • 08 Aug 2018 BioAxone Biosciences receives patent allowance for BA 1049 in USA
  • 10 Jul 2018 The USPTO issues a Notice of Allowance for composition of matter patent covering BA 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top